Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

Baricitinib Also Appears Effective in Biologic-Refractory RA

Reuters Staff  |  February 21, 2018

NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…

Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

David Douglas  |  February 16, 2018

NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…

Menopause Linked with Functional Decline in Rheumatoid Arthritis

Scott Baltic  |  February 14, 2018

NEW YORK (Reuters Health)—In women with rheumatoid arthritis (RA), menopause is associated with both functional decline and an acceleration of that decline, according to a longitudinal study from the U.S. However, several factors involving increased hormonal exposure were associated with less-severe functional decline in women with RA: ever having received hormonal replacement therapy (HRT), ever…

Is It Cold in Here? Working in Cold Environments Linked to RA

Richard Quinn  |  February 14, 2018

Novel research has linked cold environments—with snow, ice and overall frigid conditions—to an increased risk of developing rheumatoid arthritis. This research has many rheumatologists eager for more research that could aid patients and further the understanding of the disease…

Service Dogs Aid RA Patients with Mobility, Chores, Companionship & More

Karen Appold  |  January 30, 2018

Patients with severe RA can struggle with walking, getting dressed, carrying items and more, all of which can negatively affect their quality of life. But according to Bharat Kumar, MD, service dogs can help RA patients by providing both physical and emotional support, aiding patient mobility and quality of life…

Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks

Lorraine L. Janeczko  |  January 16, 2018

NEW YORK (Reuters Health)—Patients with rheumatoid arthritis (RA) are at increased risk of serious infections, myocardial infarction (MI) and coronary heart disease (CHD), an analysis of Medicare claims data suggests. “Higher disease activity as measured by a panel of biomarkers was associated with higher rates of hospitalized infections, MI and CHD events. These findings add…

The Diagnosis: How to Advise Newly Diagnosed RA Patients

Karen Appold  |  January 8, 2018

Receiving an RA diagnosis may be emotional and difficult for patients. By engaging the patient in learning about the disease and its treatment options, as well as cultivating a communicative relationship, rheumatologists can truly help a patient take control of their health…

Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis

Lara C. Pullen, PhD  |  January 8, 2018

In a 78-week study examining the interchangeability of infliximab with the biosimilar SB2, the treatments demonstrated long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis. Across all the study’s treatment groups, patients had similar treatment response rates, and the long-term clinical profile of SB2 was comparable with infliximab…

Update on ACR’s Rheumatology-Specific APM

Mary Beth Nierengarten  |  January 5, 2018

Efforts by the ACR to develop a rheumatology-specific alternative payment model (APM) are well under way. The first draft proposal was approved by the ACR Board of Directors in November and presented to the rheumatology community during the 2017 ACR/ARHP Annual Meeting in San Diego. The ACR is pursuing the development of a rheumatology-specific APM…

Pedometers & RA: Does Increasing Physical Activity Decrease Fatigue?

Arthritis Care & Research  |  January 2, 2018

Recent research examined the effectiveness of a pedometer-based intervention for managing fatigue in patients with rheumatoid arthritis (RA). During the 21-week trial, RA patients using pedometers successfully increased their physical activity, with a greater than 30% decrease in the proportion of participants classified as sedentary. Patients also decreased their reported fatigue, and some reported improvements in function, pain, depressive symptoms and disease activity levels…

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences